All In Biotech

Free tool

FAERS Monitor: Daxxify

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761127 or its brand name (Daxxify, Daxibotulinumtoxina-Lanm). Reports on generic versions are filed under their own applications.

Reports

5,969

Serious

5,181

87% of reports

Hospitalization

2,323

Death reported

1,844

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,430
  • drug ineffective1,941
  • drug intolerance1,370
  • product use in unapproved indication1,345
  • headache1,188
  • migraine1,122
  • nausea1,111
  • hypoaesthesia1,018
  • maternal exposure during pregnancy981
  • pain962
  • hypertension934
  • dizziness916
  • gastrooesophageal reflux disease915
  • epilepsy899
  • blepharospasm860

Reports by year received

View as table
YearReports
20046
20057
20062
20073
200831
200946
201042
201194
2012562
201313
201411
201512
201616
201724
201855
2019138
2020229
2021470
2022491
2023560
20241,059
20251,340
2026758

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blepharospasmSignal860556.9520.7411,801
epilepsySignal899106.7100.491,416
drug intoleranceSignal1,37050.748.466,023
migraineSignal1,12241.939.744,425
gastrooesophageal reflux diseaseSignal91540.538.134,943
maternal exposure during pregnancySignal98139.237.036,238
hypoaesthesiaSignal1,01824.122.822,547
product use in unapproved indicationSignal1,34519.218.323,364
hypertensionSignal93415.614.712,824
off label useSignal2,4309.89.519,979
headacheSignal1,1886.76.45,906
dizzinessSignal9166.56.14,336
painSignal9625.55.23,662
drug ineffectiveSignal1,9415.25.07,001
nauseaSignal1,1115.04.73,632

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.